ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Myocardial Infarction

October 4, 2020
The authors are concerned about the 'deaths at home' having the greatest contribution to the excess of acute cardiovascular deaths in that period of the recent epidemic, AND LOCKDOWN in England and Wales.
October 1, 2020
Death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome was reduced (P=0.005) by early pharmacogical or inteventional ablation for fast response-atrial fibrillation in a small German RCT. 
September 15, 2020
An open-access large metanalysis on the utility and risks of antiplatelets after PCI. Of note, mortality was not a primary endpoint. The message is that long dual antiplatelet use is an exchange between avoidance of myocardial events and serious bleeding. The novel oral anticoagulants may enter the arena soon..
May 23, 2020
a readable review that advances the position that  Adolphe Quetelet's formula is now clinically obsolete     
April 13, 2020
Topical review on the epidemic in Britain, with a number of observations that relate to the cardiothoracic surgeons and all healthcare professionals: -The assertion that the National Health Service in Britain was overrun PRIOR to the pandemic. -The assertion that acute angina is now being undertreated.
April 9, 2020
Another refreshing change of pace with an interesting pre-translational contibution to the genetics of atrial dysrhythmias.
April 3, 2020
In the ISCHEMIA Trial, 5179 patients with moderate or severe myocardial ischemia were randomized equally into two groups based on initial management strategy: initial invasive strategy (angiography and revascularization when feasible) and medical therapy, or initial conservative strategy (medical therapy alone and angiography if medical therapy faile
April 1, 2020
Short but promising follow-up: the intervention appears again to trade off short-term peripheral vascular complications for hitherto semi-qualified MAJOR bleed in patients undergoing revascularization for peripheral vascular disease, for an assumed considerable financial cost.
November 18, 2019
An editorial related to a recent randomized controlled trial suggesting a striking benefit of anti-inflammatory secondary prevention after recent myocardial events.

Pages